Loading…
Antilipase and antiproliferative activities of novel fluoroquinolones and triazolofluoroquinolones
Fluoroquinolones (FQs) have been identified recently as potent inhibitors of pancreatic lipase (PL). The aim of this study was to synthesize novel FQs and triazolofluoroquinolones (TFQs) and to evaluate them in vitro with respect to their antilipolytic efficacy and potency properties. The PL‐IC50 va...
Saved in:
Published in: | Chemical biology & drug design 2017-12, Vol.90 (6), p.1282-1294 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c3299-277b7a0e8c918aac0bf2643c894173af1e4b6656671faadd764408e8fba99c63 |
---|---|
cites | cdi_FETCH-LOGICAL-c3299-277b7a0e8c918aac0bf2643c894173af1e4b6656671faadd764408e8fba99c63 |
container_end_page | 1294 |
container_issue | 6 |
container_start_page | 1282 |
container_title | Chemical biology & drug design |
container_volume | 90 |
creator | Arabiyat, Shereen Kasabri, Violet Al‐Hiari, Yusuf Bustanji, Yasser K. Albashiti, Rabab Almasri, Ihab M. Sabbah, Dima A. |
description | Fluoroquinolones (FQs) have been identified recently as potent inhibitors of pancreatic lipase (PL). The aim of this study was to synthesize novel FQs and triazolofluoroquinolones (TFQs) and to evaluate them in vitro with respect to their antilipolytic efficacy and potency properties. The PL‐IC50 values of 12 FQs and TFQs (3 (a–c)–6 (a–c)) were in the range of 12.5–189.1 μm. These values are further supported by docking studies. The suggested association between obesity and colorectal cancer initiated the evaluation of antiproliferative activity of the new FQs and TFQs against a panel of obesity‐related colorectal cells (HT29, HCT116, SW620 CACO2, and SW480). Sulforodamine B colorimetric assay revealed that some derivatives exhibited unselective cytotoxicity against HT29, HCT116, SW620 CACO2, and SW480. Remarkably, FQ 4a's selective cytotoxicity against HCT116 was found valuable with IC50 value of 4.2 μm which exceeds that of cisplatin with a substantial selective cytotoxicity in periodontal ligament fibroblasts. In conclusion, FQ and TFQ derivatives may unveil new antiobesity and anticancer agents in the future.
Novel FQs and TFQs are synthesized and evaluated in vitro with respect to their antilipolytic and antiproliferative efficacy and potency properties. The PL‐IC50 values of 12 FQs and TFQs (3 (a–c)–6 (a–c)) were in the range of 12.5–189.1 μm. FQ 4a's selective cytotoxicity against HCT116 was found valuable with IC50 value of 4.2 μm which exceeds that of cisplatin. |
doi_str_mv | 10.1111/cbdd.13049 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1912615744</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1912615744</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3299-277b7a0e8c918aac0bf2643c894173af1e4b6656671faadd764408e8fba99c63</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRS0EoqWw4QNQlggpxU4cP5al5SVVYtO95Ti2ZOTGIU6KytfjkNIFC0ayZjxz5tq6AFwjOEcx7lVZVXOUQ8xPwBRRTFOYseL0WFM6ARchvEOIcZGxczDJGMl5XrApKBd1Z51tZNCJrKt4Otu03lmjW9nZXeyqmGxndUi8SWq_0y4xrvet_-ht7Z2v42RY7Vorv-L97_ASnBnpgr465BnYPD1uli_p-u35dblYpyrPOE_jN0sqoWaKIyalgqXJCM4V4xjRXBqkcUlIQQhFRsqqogRjyDQzpeRckXwGbkfZZnhch05sbVDaOVlr3weBOMoIKijGEb0bUdX6EFptRNParWz3AkExWCoGS8WPpRG-Oej25VZXR_TXwwigEfi0Tu__kRLLh9VqFP0GfYuECg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1912615744</pqid></control><display><type>article</type><title>Antilipase and antiproliferative activities of novel fluoroquinolones and triazolofluoroquinolones</title><source>Wiley</source><creator>Arabiyat, Shereen ; Kasabri, Violet ; Al‐Hiari, Yusuf ; Bustanji, Yasser K. ; Albashiti, Rabab ; Almasri, Ihab M. ; Sabbah, Dima A.</creator><creatorcontrib>Arabiyat, Shereen ; Kasabri, Violet ; Al‐Hiari, Yusuf ; Bustanji, Yasser K. ; Albashiti, Rabab ; Almasri, Ihab M. ; Sabbah, Dima A.</creatorcontrib><description>Fluoroquinolones (FQs) have been identified recently as potent inhibitors of pancreatic lipase (PL). The aim of this study was to synthesize novel FQs and triazolofluoroquinolones (TFQs) and to evaluate them in vitro with respect to their antilipolytic efficacy and potency properties. The PL‐IC50 values of 12 FQs and TFQs (3 (a–c)–6 (a–c)) were in the range of 12.5–189.1 μm. These values are further supported by docking studies. The suggested association between obesity and colorectal cancer initiated the evaluation of antiproliferative activity of the new FQs and TFQs against a panel of obesity‐related colorectal cells (HT29, HCT116, SW620 CACO2, and SW480). Sulforodamine B colorimetric assay revealed that some derivatives exhibited unselective cytotoxicity against HT29, HCT116, SW620 CACO2, and SW480. Remarkably, FQ 4a's selective cytotoxicity against HCT116 was found valuable with IC50 value of 4.2 μm which exceeds that of cisplatin with a substantial selective cytotoxicity in periodontal ligament fibroblasts. In conclusion, FQ and TFQ derivatives may unveil new antiobesity and anticancer agents in the future.
Novel FQs and TFQs are synthesized and evaluated in vitro with respect to their antilipolytic and antiproliferative efficacy and potency properties. The PL‐IC50 values of 12 FQs and TFQs (3 (a–c)–6 (a–c)) were in the range of 12.5–189.1 μm. FQ 4a's selective cytotoxicity against HCT116 was found valuable with IC50 value of 4.2 μm which exceeds that of cisplatin.</description><identifier>ISSN: 1747-0277</identifier><identifier>EISSN: 1747-0285</identifier><identifier>DOI: 10.1111/cbdd.13049</identifier><identifier>PMID: 28639358</identifier><language>eng</language><publisher>England</publisher><subject>Antineoplastic Agents - chemical synthesis ; Antineoplastic Agents - chemistry ; Antineoplastic Agents - pharmacology ; Binding Sites ; Caco-2 Cells ; Catalytic Domain ; Cell Line, Tumor ; Cell Survival - drug effects ; colorectal cancer ; fluoroquinolones ; Fluoroquinolones - chemical synthesis ; Fluoroquinolones - chemistry ; Fluoroquinolones - pharmacology ; Humans ; Hydrogen Bonding ; Inhibitory Concentration 50 ; Molecular Docking Simulation ; pancreatic triacylglycerol lipase ; Pancrelipase - antagonists & inhibitors ; Pancrelipase - metabolism ; Structure-Activity Relationship ; Thermodynamics ; triazolofluoroquinolones</subject><ispartof>Chemical biology & drug design, 2017-12, Vol.90 (6), p.1282-1294</ispartof><rights>2017 John Wiley & Sons A/S</rights><rights>2017 John Wiley & Sons A/S.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3299-277b7a0e8c918aac0bf2643c894173af1e4b6656671faadd764408e8fba99c63</citedby><cites>FETCH-LOGICAL-c3299-277b7a0e8c918aac0bf2643c894173af1e4b6656671faadd764408e8fba99c63</cites><orcidid>0000-0001-7456-2848 ; 0000-0003-1428-5097</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28639358$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Arabiyat, Shereen</creatorcontrib><creatorcontrib>Kasabri, Violet</creatorcontrib><creatorcontrib>Al‐Hiari, Yusuf</creatorcontrib><creatorcontrib>Bustanji, Yasser K.</creatorcontrib><creatorcontrib>Albashiti, Rabab</creatorcontrib><creatorcontrib>Almasri, Ihab M.</creatorcontrib><creatorcontrib>Sabbah, Dima A.</creatorcontrib><title>Antilipase and antiproliferative activities of novel fluoroquinolones and triazolofluoroquinolones</title><title>Chemical biology & drug design</title><addtitle>Chem Biol Drug Des</addtitle><description>Fluoroquinolones (FQs) have been identified recently as potent inhibitors of pancreatic lipase (PL). The aim of this study was to synthesize novel FQs and triazolofluoroquinolones (TFQs) and to evaluate them in vitro with respect to their antilipolytic efficacy and potency properties. The PL‐IC50 values of 12 FQs and TFQs (3 (a–c)–6 (a–c)) were in the range of 12.5–189.1 μm. These values are further supported by docking studies. The suggested association between obesity and colorectal cancer initiated the evaluation of antiproliferative activity of the new FQs and TFQs against a panel of obesity‐related colorectal cells (HT29, HCT116, SW620 CACO2, and SW480). Sulforodamine B colorimetric assay revealed that some derivatives exhibited unselective cytotoxicity against HT29, HCT116, SW620 CACO2, and SW480. Remarkably, FQ 4a's selective cytotoxicity against HCT116 was found valuable with IC50 value of 4.2 μm which exceeds that of cisplatin with a substantial selective cytotoxicity in periodontal ligament fibroblasts. In conclusion, FQ and TFQ derivatives may unveil new antiobesity and anticancer agents in the future.
Novel FQs and TFQs are synthesized and evaluated in vitro with respect to their antilipolytic and antiproliferative efficacy and potency properties. The PL‐IC50 values of 12 FQs and TFQs (3 (a–c)–6 (a–c)) were in the range of 12.5–189.1 μm. FQ 4a's selective cytotoxicity against HCT116 was found valuable with IC50 value of 4.2 μm which exceeds that of cisplatin.</description><subject>Antineoplastic Agents - chemical synthesis</subject><subject>Antineoplastic Agents - chemistry</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Binding Sites</subject><subject>Caco-2 Cells</subject><subject>Catalytic Domain</subject><subject>Cell Line, Tumor</subject><subject>Cell Survival - drug effects</subject><subject>colorectal cancer</subject><subject>fluoroquinolones</subject><subject>Fluoroquinolones - chemical synthesis</subject><subject>Fluoroquinolones - chemistry</subject><subject>Fluoroquinolones - pharmacology</subject><subject>Humans</subject><subject>Hydrogen Bonding</subject><subject>Inhibitory Concentration 50</subject><subject>Molecular Docking Simulation</subject><subject>pancreatic triacylglycerol lipase</subject><subject>Pancrelipase - antagonists & inhibitors</subject><subject>Pancrelipase - metabolism</subject><subject>Structure-Activity Relationship</subject><subject>Thermodynamics</subject><subject>triazolofluoroquinolones</subject><issn>1747-0277</issn><issn>1747-0285</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp9kMtOwzAQRS0EoqWw4QNQlggpxU4cP5al5SVVYtO95Ti2ZOTGIU6KytfjkNIFC0ayZjxz5tq6AFwjOEcx7lVZVXOUQ8xPwBRRTFOYseL0WFM6ARchvEOIcZGxczDJGMl5XrApKBd1Z51tZNCJrKt4Otu03lmjW9nZXeyqmGxndUi8SWq_0y4xrvet_-ht7Z2v42RY7Vorv-L97_ASnBnpgr465BnYPD1uli_p-u35dblYpyrPOE_jN0sqoWaKIyalgqXJCM4V4xjRXBqkcUlIQQhFRsqqogRjyDQzpeRckXwGbkfZZnhch05sbVDaOVlr3weBOMoIKijGEb0bUdX6EFptRNParWz3AkExWCoGS8WPpRG-Oej25VZXR_TXwwigEfi0Tu__kRLLh9VqFP0GfYuECg</recordid><startdate>201712</startdate><enddate>201712</enddate><creator>Arabiyat, Shereen</creator><creator>Kasabri, Violet</creator><creator>Al‐Hiari, Yusuf</creator><creator>Bustanji, Yasser K.</creator><creator>Albashiti, Rabab</creator><creator>Almasri, Ihab M.</creator><creator>Sabbah, Dima A.</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7456-2848</orcidid><orcidid>https://orcid.org/0000-0003-1428-5097</orcidid></search><sort><creationdate>201712</creationdate><title>Antilipase and antiproliferative activities of novel fluoroquinolones and triazolofluoroquinolones</title><author>Arabiyat, Shereen ; Kasabri, Violet ; Al‐Hiari, Yusuf ; Bustanji, Yasser K. ; Albashiti, Rabab ; Almasri, Ihab M. ; Sabbah, Dima A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3299-277b7a0e8c918aac0bf2643c894173af1e4b6656671faadd764408e8fba99c63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Antineoplastic Agents - chemical synthesis</topic><topic>Antineoplastic Agents - chemistry</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Binding Sites</topic><topic>Caco-2 Cells</topic><topic>Catalytic Domain</topic><topic>Cell Line, Tumor</topic><topic>Cell Survival - drug effects</topic><topic>colorectal cancer</topic><topic>fluoroquinolones</topic><topic>Fluoroquinolones - chemical synthesis</topic><topic>Fluoroquinolones - chemistry</topic><topic>Fluoroquinolones - pharmacology</topic><topic>Humans</topic><topic>Hydrogen Bonding</topic><topic>Inhibitory Concentration 50</topic><topic>Molecular Docking Simulation</topic><topic>pancreatic triacylglycerol lipase</topic><topic>Pancrelipase - antagonists & inhibitors</topic><topic>Pancrelipase - metabolism</topic><topic>Structure-Activity Relationship</topic><topic>Thermodynamics</topic><topic>triazolofluoroquinolones</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Arabiyat, Shereen</creatorcontrib><creatorcontrib>Kasabri, Violet</creatorcontrib><creatorcontrib>Al‐Hiari, Yusuf</creatorcontrib><creatorcontrib>Bustanji, Yasser K.</creatorcontrib><creatorcontrib>Albashiti, Rabab</creatorcontrib><creatorcontrib>Almasri, Ihab M.</creatorcontrib><creatorcontrib>Sabbah, Dima A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Chemical biology & drug design</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Arabiyat, Shereen</au><au>Kasabri, Violet</au><au>Al‐Hiari, Yusuf</au><au>Bustanji, Yasser K.</au><au>Albashiti, Rabab</au><au>Almasri, Ihab M.</au><au>Sabbah, Dima A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antilipase and antiproliferative activities of novel fluoroquinolones and triazolofluoroquinolones</atitle><jtitle>Chemical biology & drug design</jtitle><addtitle>Chem Biol Drug Des</addtitle><date>2017-12</date><risdate>2017</risdate><volume>90</volume><issue>6</issue><spage>1282</spage><epage>1294</epage><pages>1282-1294</pages><issn>1747-0277</issn><eissn>1747-0285</eissn><abstract>Fluoroquinolones (FQs) have been identified recently as potent inhibitors of pancreatic lipase (PL). The aim of this study was to synthesize novel FQs and triazolofluoroquinolones (TFQs) and to evaluate them in vitro with respect to their antilipolytic efficacy and potency properties. The PL‐IC50 values of 12 FQs and TFQs (3 (a–c)–6 (a–c)) were in the range of 12.5–189.1 μm. These values are further supported by docking studies. The suggested association between obesity and colorectal cancer initiated the evaluation of antiproliferative activity of the new FQs and TFQs against a panel of obesity‐related colorectal cells (HT29, HCT116, SW620 CACO2, and SW480). Sulforodamine B colorimetric assay revealed that some derivatives exhibited unselective cytotoxicity against HT29, HCT116, SW620 CACO2, and SW480. Remarkably, FQ 4a's selective cytotoxicity against HCT116 was found valuable with IC50 value of 4.2 μm which exceeds that of cisplatin with a substantial selective cytotoxicity in periodontal ligament fibroblasts. In conclusion, FQ and TFQ derivatives may unveil new antiobesity and anticancer agents in the future.
Novel FQs and TFQs are synthesized and evaluated in vitro with respect to their antilipolytic and antiproliferative efficacy and potency properties. The PL‐IC50 values of 12 FQs and TFQs (3 (a–c)–6 (a–c)) were in the range of 12.5–189.1 μm. FQ 4a's selective cytotoxicity against HCT116 was found valuable with IC50 value of 4.2 μm which exceeds that of cisplatin.</abstract><cop>England</cop><pmid>28639358</pmid><doi>10.1111/cbdd.13049</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0001-7456-2848</orcidid><orcidid>https://orcid.org/0000-0003-1428-5097</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1747-0277 |
ispartof | Chemical biology & drug design, 2017-12, Vol.90 (6), p.1282-1294 |
issn | 1747-0277 1747-0285 |
language | eng |
recordid | cdi_proquest_miscellaneous_1912615744 |
source | Wiley |
subjects | Antineoplastic Agents - chemical synthesis Antineoplastic Agents - chemistry Antineoplastic Agents - pharmacology Binding Sites Caco-2 Cells Catalytic Domain Cell Line, Tumor Cell Survival - drug effects colorectal cancer fluoroquinolones Fluoroquinolones - chemical synthesis Fluoroquinolones - chemistry Fluoroquinolones - pharmacology Humans Hydrogen Bonding Inhibitory Concentration 50 Molecular Docking Simulation pancreatic triacylglycerol lipase Pancrelipase - antagonists & inhibitors Pancrelipase - metabolism Structure-Activity Relationship Thermodynamics triazolofluoroquinolones |
title | Antilipase and antiproliferative activities of novel fluoroquinolones and triazolofluoroquinolones |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T07%3A44%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antilipase%20and%20antiproliferative%20activities%20of%20novel%20fluoroquinolones%20and%20triazolofluoroquinolones&rft.jtitle=Chemical%20biology%20&%20drug%20design&rft.au=Arabiyat,%20Shereen&rft.date=2017-12&rft.volume=90&rft.issue=6&rft.spage=1282&rft.epage=1294&rft.pages=1282-1294&rft.issn=1747-0277&rft.eissn=1747-0285&rft_id=info:doi/10.1111/cbdd.13049&rft_dat=%3Cproquest_cross%3E1912615744%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3299-277b7a0e8c918aac0bf2643c894173af1e4b6656671faadd764408e8fba99c63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1912615744&rft_id=info:pmid/28639358&rfr_iscdi=true |